Feasibility of advanced stereotactic radiotherapy for brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility of using advanced stereotactic radiotherapy (iHD-SRT) for patients with brain metastases. It focuses on patients with measurable lesions who can undergo this precise treatment, which aims to improve tumor control while minimizing cognitive side effects. The study is designed to assess the effectiveness of this approach compared to traditional methods, with a focus on patient survival and quality of life. The use of high-resolution technology allows for greater accuracy in targeting tumors, potentially leading to better outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to understand and willingness to participate the research and sign the consent form
* ECOG PS 0-2
* The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor
* Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume)
* Estimated survival time ≥ 3 months

Exclusion Criteria:

* Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT
* With severe internal medicine complications or absolute contraindications for radiotherapy
* other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc

Where it's running

• Ruijin Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jiayi Chen — Ruijin Hospital
• Study coordinator: Dan Ou, MD
• Email: od12341@rjh.com.cn
• Phone: 8618801970632

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• AI-assisted diagnosis for malignant brain tumors

  This project will test an AI system that uses routine preoperative MRI scans to automatically segment and classify malignant brain tumors in adults to help guide diagnosis and care.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07198256

• Same-day stereotactic radiation with reduced planning margins for growing or changing brain metastases

  This trial will try to see if doing MRI planning and stereotactic radiation on the same day, with either a 0 mm or 1 mm treatment margin, helps adults with growing or unstable brain metastases stay on target and reduce side effects.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07132190

• Preventing first seizures with levetiracetam in patients with motor cortex brain metastases

  This test will try giving levetiracetam to adults with motor cortex brain metastases who have never had a seizure to see if it prevents a first seizure compared with not giving the drug.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07130786

• Avoiding brain radiation when systemic therapy already targets brain metastases

  This pilot trial tests whether patients with brain metastases who respond to systemic therapy can skip brain radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06974370

• Using ex vivo pharmacoscopy to guide treatment for brain metastases

  This project will test whether pharmacoscopy, a lab test that screens a patient's tumor cells against many drugs, can help pick effective treatments for adults having surgery for brain metastases.

  Recruiting at 2 sites Phase 2 University of Zurich · Basel and 2 other locations · NCT06620380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.